证券代码：000661 证券简称：长春高新 公告编号：2023-031 长春高新技术产业（集团）股份有限公司 关于举办 2022 年度及 2023 年第一季度业绩说明会的公告 （投资者提问征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日披露 2022 年年度报告，并拟于 2023 年 4 月 18 日披露 2023 年第一 季度报告。为便于广大投资者进一步了解公司 2022 年度及 2023 年第一季度生 产经营情况及未来发展规划，公司定于 2023 年 4 月 21 日（星期五）13:30- 17:00 举办 2022 年度及 2023 年第一季度业绩说明会。本次业绩说明会采用网 络视频直播的方式举行，欢迎广大投资者积极参与。 一、业绩说明会的安排 1、召开时间：2023 年 4 月 21 日 13:30-17:00 4、出席人员 董事长马骥先生，董事、总经理姜云涛先生，董事、常务副总经理叶朋先 生，独立董事李春好先生，副总经理李秀峰先生，副总经 ...

Financial Performance - The company's operating revenue for 2022 was CNY 12,627,188,966.71, representing a 17.50% increase compared to CNY 10,746,717,262.21 in 2021[19]. - The net profit attributable to shareholders of the listed company was CNY 4,140,114,115.74, an increase of 10.18% from CNY 3,757,472,953.11 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 4,118,413,628.66, up 10.06% from CNY 3,742,099,607.18 in 2021[19]. - The basic earnings per share for 2022 was CNY 10.29, reflecting a 10.88% increase from CNY 9.28 in 2021[19]. - The total assets at the end of 2022 were CNY 26,027,362,994.80, a 15.60% increase from CNY 22,515,769,520.78 at the end of 2021[19]. - The net assets attributable to shareholders of the listed company increased by 23.85% to CNY 18,049,805,753.49 from CNY 14,573,728,469.70 in the previous year[19]. - The net cash flow from operating activities decreased by 15.14% to CNY 2,826,408,333.06 from CNY 3,330,619,225.29 in 2021[19]. - The weighted average return on equity was 25.71%, down from 28.81% in the previous year, indicating a decrease of 3.10%[19]. Revenue and Profit Breakdown - In 2022, the company's total revenue for the four quarters was approximately CNY 12.63 billion, with the highest revenue in Q3 at CNY 3.81 billion[23]. - The net profit attributable to shareholders for the year was approximately CNY 4.14 billion, with Q1 showing the highest profit of CNY 1.14 billion[23]. - The net cash flow from operating activities for the year totaled approximately CNY 2.83 billion, with Q4 contributing the most at CNY 1.23 billion[23]. - The pharmaceutical sector contributed ¥11,948,609,181.07, accounting for 94.63% of total revenue, with a growth of 18.93% from ¥10,046,374,067.81 in 2021[60]. - Gene engineering and biological drugs generated ¥11,290,164,405.57, which is 89.42% of total revenue, showing a 20.05% increase from ¥9,404,719,539.29 in the previous year[60]. Research and Development - R&D investment reached 1.663 billion yuan, showing a significant increase of 52.26% year-on-year[48]. - The proportion of R&D investment to operating revenue increased by 3.01% to 13.17% in 2022[77]. - R&D personnel increased by 17.30% to 1,146 in 2022, with the proportion of R&D staff rising to 12.96% of total employees[76]. - The company is investing heavily in R&D, with an allocation of 200 million yuan for the development of new biopharmaceuticals and vaccines in the upcoming year[34]. - The company is conducting Phase III clinical trials for recombinant human growth hormone injection for chronic kidney disease-related growth disorders[73]. - The company is also in Phase II clinical trials for polyethylene glycol recombinant human growth hormone injection for various growth disorders[73]. Market Expansion and Product Development - The company has set a revenue guidance for the next fiscal year, projecting a growth rate of 25% to 30%[34]. - New product launches include a series of innovative vaccines, such as the varicella live attenuated vaccine and the inactivated rabies vaccine, aimed at enhancing the company's market position in the vaccine sector[34]. - The company is actively expanding its product lines in assisted reproduction and women's health, aiming for dual growth in its main business areas[40]. - The company is focusing on optimizing its product innovation and enhancing operational performance through a robust marketing team of approximately 4,100 personnel[46]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of 500 million yuan allocated for this purpose in 2023[121]. Corporate Governance and Management - The company has a governance structure that ensures independence from its controlling shareholder, maintaining a complete business system and financial independence[106]. - The board of directors consists of 9 members, including 3 independent directors, ensuring effective governance and decision-making[106]. - The company has established a multi-level incentive system to attract and retain quality talent, focusing on internal promotion and external recruitment[100]. - The company has implemented a strict insider information management system to prevent leaks during the preparation of periodic reports and major events[108]. - The company has conducted multiple investor communications, including a conference call with 231 institutional investors to discuss operational performance[103]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to multiple environmental protection laws and standards[156]. - The company has publicly disclosed its environmental, social, and governance (ESG) report for 2022, detailing its social responsibility efforts[173]. - The company has made significant investments in environmental protection initiatives as part of its corporate social responsibility strategy[171]. - The company has undergone environmental impact assessments for its construction projects, ensuring compliance with environmental regulations[158]. - The company has established effective waste gas treatment systems in its workshops and R&D facilities[168]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion yuan[117]. - The company plans to enhance operational efficiency, targeting a reduction in costs by 15% through process optimization initiatives[123]. - The company is focused on maintaining its independence and operational capabilities, ensuring no conflicts with controlling shareholders[109]. - The company is committed to enhancing its core competitiveness through product structure improvement, sales model optimization, and new business development[98].

Management and Leadership - Chairman Yang Zhanzhong's retirement has been postponed for five years to maintain management stability during a critical transformation period [3] - The management team is expected to remain largely unchanged after the upcoming board restructuring [3] Business Strategy - The company will continue to focus on the biopharmaceutical industry, increasing financial and operational investments in related sectors [4] - The management model will emphasize investment holding and enhanced hierarchical management capabilities [4] - The company does not plan to divest from the real estate sector but will implement risk control measures regarding investment proportions [4] Financial Performance - Jin Sai Pharmaceutical has shown slight growth in various indicators compared to the previous year, although growth rates have slowed compared to earlier years [5] - The impact of the "Changsha incident" on new patient enrollment rates is expected to affect sales in the fourth quarter [5] - The real estate sector is projected to see an increase in settlement income compared to the previous year, despite fluctuations in quarterly income due to having only one development project [11] Product Development - The long-acting growth hormone injection requires approximately three years to complete Phase IV clinical trials [6] - The company anticipates receiving GMP certification for the follicle-stimulating hormone product in the second quarter of next year, with market launch expected in the third quarter [7] - The rabies vaccine production is undergoing cautious production adjustments, with a long production cycle of at least nine months before market availability [9] Market and Sales Strategy - Jin Sai's sales strategy focuses on hospitals and cooperative clinics, with an emphasis on collaboration with small and medium-sized hospitals [10] - The company has registered its long-acting growth hormone in about six small countries, with plans to expand further [10] - The pricing of long-acting growth hormone is influenced by various factors, including patient age and weight, making it difficult to standardize annual costs [9] Regulatory and Compliance - The company is cautious regarding the production of vaccines and is addressing any adverse reactions from previous incidents [9] - The impact of the VAT policy adjustment on profits is expected to be positive, effective from July 1, 2014 [15] Future Outlook - The company expresses confidence in its future development, attributing this to teamwork and shareholder support, although stock price predictions remain uncertain due to multiple influencing factors [18] - The management is open to various acquisition models, emphasizing the importance of enhancing integration capabilities before proceeding [12]

Group 1: Urban Renewal Project - The urban renewal project in Changchun High-tech Zone is part of the national initiative to revitalize Northeast China and improve living conditions [3] - The project will be funded through long-term low-interest loans from the National Development Bank, with Changchun Gaoxin Real Estate Development Co., Ltd. responsible for implementation [3] - The project is currently in the preliminary stages, with no significant impact on the company's performance expected in the short term [4] Group 2: Company Structure and Strategy - The company focuses on biopharmaceuticals and health industries as its primary direction, with real estate development as a supplementary business [4] - In biopharmaceuticals, the company is actively developing production technology platforms for genetic engineering, biological vaccines, peptide synthesis, and herbal medicines [4] Group 3: Financial Performance and Sales Strategy - Jin Sai Pharmaceutical's third-quarter performance growth is attributed to effective sales policy adjustments, stabilization of powder injection prices, and successful summer marketing activities [5] - The sales strategy for long-acting growth hormone focuses on major hospitals while also expanding into smaller hospitals and clinics in second-tier and grassroots cities [5] - The long-acting growth hormone is a globally innovative product, with promotional measures including expert clinical guidance to enhance product understanding among doctors and patients [5] Group 4: Competitive Pricing - The pricing of follicle-stimulating hormone will be slightly lower than that of imported products, maintaining a competitive price advantage [5]

Funding and Financial Strategy - The company plans to raise CNY 1.4 billion for working capital to support product development and marketing channel construction [1] - The choice of rights issue for refinancing is due to its relatively convenient approval process, which helps meet funding needs efficiently [2] Investment Strategy - The company focuses on the health industry, aiming to invest in high-tech products and high-growth sectors [3] - A new corporate development department has been established to select and evaluate industry projects, leveraging experienced intermediaries for project sourcing [4] Project Development and Sales Channels - The company is interested in cutting-edge biotechnologies, including cell therapy, but is awaiting technology validation before proceeding with specific projects [5] - Progress is ongoing in building sales channels, with a team of professionals being developed and specific plans under evaluation [6] Project Funding and Management - The company will not wait for the rights issue funds to be in place before advancing mature projects, utilizing its own funds or other financing methods instead [7] - The management is optimistic about achieving the operational targets set by the board, with expected profit growth not lower than the industry average [8]

Group 1: Company Direction and Strategy - The company maintains its focus on biopharmaceuticals and related industries, asserting that its core business direction will not change despite winning a real estate project worth over 10 billion [3] - The company emphasizes two unwavering commitments: maintaining its primary business in biopharmaceuticals and pursuing innovation as a growth strategy [3] Group 2: Subsidiary and Market Engagement - The company is open to utilizing multi-tiered capital markets for the development of its subsidiaries while ensuring it retains control over them [4] - The company is closely monitoring the development of multi-tiered capital markets and studying relevant cases [4] Group 3: Product Development and Investment - The company plans to allocate 800 million for new product research and development from the proceeds of its fundraising [5] - New product development includes a range of projects such as assisted reproductive products, original monoclonal antibodies for cancer and inflammation, and vaccines for various diseases [6]

Group 1: Clinical Progress and Product Development - The long-acting growth hormone clinical trial is progressing smoothly, with completion expected in 2017 [1] - The new product, follicle-stimulating hormone, is being positioned in the market and is anticipated to perform well due to its mature product status and advanced recombinant technology [2] - The sales of growth hormone powder and water injections are expected to continue growing [2] Group 2: Financial Performance and Market Strategy - Huakang Pharmaceutical experienced negative revenue growth in the first three quarters due to multiple factors including public hospital bidding price reductions and rising production costs [3] - Huakang Pharmaceutical is refining its sales strategy to expand market coverage, aiming for a certain degree of growth in performance next year as market adjustments take place [3]

Financial Performance - The company achieved a revenue of 1.07 billion CNY in the first half of the year, representing a year-on-year growth of 22.62% [3] - The net profit attributable to shareholders was 170 million CNY, with a year-on-year increase of 62.27% [3] - The pharmaceutical segment generated 860 million CNY in revenue, growing by 4.99%, and net profit of 150 million CNY, up by 16.39% [3] Product Development and Market Strategy - JinSai Pharmaceutical's net profit reached 180 million CNY, marking a 15.11% increase [3] - The GMP certification for follicle-stimulating hormone has been announced, allowing for official production and sales [4] - The company is exploring a marketing model through the establishment of Shanghai Tongxin Hospital Management Company to enhance competitive positioning [4][5] Market Trends and Challenges - The pharmaceutical industry is facing challenges due to mandatory price reductions and regulatory constraints from public hospital procurement [3] - The sales growth of the pharmaceutical segment is showing signs of slowing down due to external and internal factors [3] Future Outlook and Innovations - The company is focusing on the development of thymosin α1 and other potential products, with a strong emphasis on growth hormone sales [6] - Plans for mergers and acquisitions are centered on the health industry, with a focus on innovative development and market expansion [7][8] - The long-acting growth hormone is expected to gain market acceptance as it progresses through clinical phases [8]

Group 1: Company Control and Management - The change of the actual controller to Changchun Longxiang Group will not impact the company's development strategy or daily operations [3] - The local state-owned enterprise reform implementation measures have not yet been released, awaiting guidance from relevant authorities [3] - The increase in stock holdings by directors, supervisors, and executives is a voluntary action based on confidence in the company's future, not a regulatory requirement [4] Group 2: Market and Product Development - The market sales of long-acting growth hormone are progressing as planned, with sales performance meeting expectations [6] - The production of follicle-stimulating hormone is being organized, with sales expected to commence as products are sold through public hospital tenders [6] - The clinical trial for the nasal spray flu vaccine is expected to take about one year, with the launch date dependent on regulatory review [7] Group 3: Investment and Partnerships - The establishment of Shanghai Tongxin Hospital Management Co., Ltd. is underway, with registration and acquisition research progressing as planned [5] - The project for the heart stent by Xi'an Aide Wansi is currently in preclinical research, showing optimistic progress [7] - The self-inspection report for the Aisena peptide project has been submitted, currently awaiting review by the regulatory department [7]